Bill Maughan
Stock Analyst at Clear Street
(0.85)
# 4,047
Out of 5,241 analysts
23
Total ratings
31.25%
Success rate
-14.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Bill Maughan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DNTH Dianthus Therapeutics | Maintains: Buy | $100 → $130 | $83.60 | +55.50% | 2 | Mar 10, 2026 | |
| OCUL Ocular Therapeutix | Maintains: Buy | $21 → $28 | $8.38 | +234.13% | 1 | Mar 3, 2026 | |
| KRRO Korro Bio | Upgrades: Buy | $10 → $18 | $9.97 | +80.54% | 2 | Feb 19, 2026 | |
| CRBU Caribou Biosciences | Initiates: Buy | $13 | $2.07 | +528.02% | 1 | Feb 2, 2026 | |
| CLLS Cellectis | Initiates: Buy | $9 | $3.85 | +133.77% | 1 | Dec 23, 2025 | |
| WVE Wave Life Sciences | Maintains: Buy | $22 → $47 | $6.40 | +634.38% | 2 | Dec 9, 2025 | |
| ANNX Annexon | Initiates: Buy | $17 | $4.96 | +242.74% | 1 | Dec 2, 2025 | |
| KRYS Krystal Biotech | Initiates: Buy | $190 | $291.75 | -34.88% | 1 | Jul 1, 2025 | |
| CRSP CRISPR Therapeutics AG | Downgrades: Hold | $45 | $48.56 | -7.33% | 1 | Jun 27, 2025 | |
| NKTX Nkarta | Maintains: Buy | $16 → $15 | $2.68 | +459.70% | 2 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $9 | $1.73 | +420.23% | 1 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $63 → $67 | $28.37 | +136.16% | 3 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $91 → $106 | $48.11 | +120.33% | 3 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $24 | $2.28 | +952.63% | 1 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $60 | $4.36 | +1,276.15% | 1 | Feb 21, 2024 |
Dianthus Therapeutics
Mar 10, 2026
Maintains: Buy
Price Target: $100 → $130
Current: $83.60
Upside: +55.50%
Ocular Therapeutix
Mar 3, 2026
Maintains: Buy
Price Target: $21 → $28
Current: $8.38
Upside: +234.13%
Korro Bio
Feb 19, 2026
Upgrades: Buy
Price Target: $10 → $18
Current: $9.97
Upside: +80.54%
Caribou Biosciences
Feb 2, 2026
Initiates: Buy
Price Target: $13
Current: $2.07
Upside: +528.02%
Cellectis
Dec 23, 2025
Initiates: Buy
Price Target: $9
Current: $3.85
Upside: +133.77%
Wave Life Sciences
Dec 9, 2025
Maintains: Buy
Price Target: $22 → $47
Current: $6.40
Upside: +634.38%
Annexon
Dec 2, 2025
Initiates: Buy
Price Target: $17
Current: $4.96
Upside: +242.74%
Krystal Biotech
Jul 1, 2025
Initiates: Buy
Price Target: $190
Current: $291.75
Upside: -34.88%
CRISPR Therapeutics AG
Jun 27, 2025
Downgrades: Hold
Price Target: $45
Current: $48.56
Upside: -7.33%
Nkarta
May 10, 2024
Maintains: Buy
Price Target: $16 → $15
Current: $2.68
Upside: +459.70%
May 10, 2024
Maintains: Buy
Price Target: $11 → $9
Current: $1.73
Upside: +420.23%
May 9, 2024
Maintains: Hold
Price Target: $63 → $67
Current: $28.37
Upside: +136.16%
May 3, 2024
Maintains: Hold
Price Target: $91 → $106
Current: $48.11
Upside: +120.33%
Mar 15, 2024
Maintains: Buy
Price Target: $22 → $24
Current: $2.28
Upside: +952.63%
Feb 21, 2024
Reiterates: Buy
Price Target: $60
Current: $4.36
Upside: +1,276.15%